Enterprise Value
67.35M
Cash
65.0M
Avg Qtr Burn
-11.09M
Short % of Float
2.95%
Insider Ownership
2.63%
Institutional Own.
54.46%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Uproleselan (GMI-1271) Details Acute myeloid leukemia, Cancer | Phase 3 Data readout | |
Rivipansel (GMI-1070) Details SCD (Sickle Cell Disease) | Failed Discontinued | |
GMI-1359 Details Breast cancer | Failed Discontinued |